Triumph Capital Management Acquires 47,127 Shares of Organon & Co. $OGN

Key Points

• Triumph Capital Management increased its stake in Organon & Co. by 109.1% in Q2, now owning 90,342 shares valued at approximately $875,000.
• BNP Paribas upgraded Organon & Co. to a "strong-buy" rating, contributing to a consensus rating of "Moderate Buy" with a target price of $17.33.
• The company reported earnings of $1.00 EPS for the last quarter, exceeding estimates, while its revenue totaled $1.59 billion, slightly above forecasts.

Triumph Capital Management grew its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 109.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,342 shares of the company's stock after buying an additional 47,127 shares during the period. Triumph Capital Management's holdings in Organon & Co. were worth $875,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Organon & Co. by 870.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company's stock valued at $15,051,000 after purchasing an additional 906,675 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Organon & Co. by 8.3% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock worth $159,553,000 after purchasing an additional 820,378 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock worth $21,370,000 after purchasing an additional 801,307 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Organon & Co. in the fourth quarter valued at approximately $11,892,000. Finally, Siemens Fonds Invest GmbH bought a new position in Organon & Co. in the fourth quarter valued at approximately $8,998,000. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Stock Down 3.6%

OGN traded down $0.39 during trading on Friday, hitting $10.46. The company had a trading volume of 9,658,470 shares, compared to its average volume of 3,489,394. The firm's 50-day moving average price is $9.69 and its 200 day moving average price is $10.73. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. Organon & Co. has a one year low of $8.01 and a one year high of $20.09. The company has a market capitalization of $2.72 billion, a PE ratio of 3.89, a PEG ratio of 0.99 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The business's revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were given a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 annualized dividend and a dividend yield of 0.8%. Organon & Co.'s payout ratio is 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.